BOTHELL, WA -- (MARKET WIRE) -- October 27, 2006 -- Eden Bioscience Corporation (NASDAQ: EDEN) today announced that it has received a letter from the Nasdaq Stock Market notifying it that the closing price per share of the Company’s common stock was above the $1.00 minimum bid price for 10 consecutive trading days and that, as a result, the Company has regained compliance with Nasdaq’s continued listing criteria. However, the closing bid price of the Company’s common stock on October 27, 2006 was $0.69, below the $1.00 minimum bid price requirement. If the closing bid price remains below $1.00 per share for 30 consecutive trading days, the Company would again no longer meet The Nasdaq Capital Market’s minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4).
